Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
AssigneeMartek Biosciences Corporation
InventorsLinda Arterburn, James Hoffman, Harry Oken, Mary Van Elswyk
Life of this patent
Estimating the term…
Abstract
This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.
Claims21
A method for impeding the development or progression of a disease associated with subclinical inflammation consisting essentially of administering docosahexaenoic acid (DHA) to a patient in an amount effective to reduce subclinical inflammation.
A method of prophylactic therapy for subclinical inflammation consisting essentially of administering DHA to a patient having an elevated level of circulating CRP, wherein said DHA is administered in an amount sufficient to reduce circulating CRP in the patient.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating an individual at risk of having a stroke consisting essentially of:
- a) assessing an individual to determine if three or more risk factors are present wherein the risk factors are selected from abdominal obesity (men >40″ waist, women >35″), high triglycerides (≧150 mg/dL), low HDL cholesterol (men <40 mg/dL women <50 mg/dL), high blood pressure (≧130/≧85), small LDL particle size and high fasting glucose (>110 mg/dL) in combination with elevated levels of C-reactive protein;
- b) providing said individual with a dosage of DHA which is greater than about 750 mg/day for a period of more than three months.
(canceled)
(canceled)
Dependencies are inferred from the claim text.